应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VIRX Viracta Therapeutics, Inc.
盘后交易 07-23 18:22:17 EDT
0.4985
-0.0215
-4.13%
盘后
0.4881
-0.0104
-2.09%
16:07 EDT
最高
0.5100
最低
0.4834
成交量
4.15万
今开
0.5100
昨收
0.5200
日振幅
5.12%
总市值
1,958万
流通市值
1,230万
总股本
3,927万
成交额
2.06万
换手率
0.17%
流通股本
2,467万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Viracta Therapeutics, Inc.盘中异动 早盘股价大跌5.58%报0.491美元
自选股智能写手 · 07-23 22:54
Viracta Therapeutics, Inc.盘中异动 早盘股价大跌5.58%报0.491美元
Viracta Therapeutics, Inc.盘中异动 早盘大幅下挫8.68%报0.500美元
自选股智能写手 · 07-22 22:04
Viracta Therapeutics, Inc.盘中异动 早盘大幅下挫8.68%报0.500美元
Viracta Therapeutics Inc 预计每股亏损 35 美分 - 财报前瞻
Reuters · 05-03
Viracta Therapeutics Inc 预计每股亏损 35 美分 - 财报前瞻
Viracta Therapeutics Inc 预计每股亏损 29 美分 - 财报前瞻
Reuters · 03-08
Viracta Therapeutics Inc 预计每股亏损 29 美分 - 财报前瞻
加载更多
公司概况
公司名称:
Viracta Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Viracta Therapeutics, Inc.于1998年2月10日在特拉华州注册成立。其子公司主要位于南旧金山、加利福尼亚州。Viracta是一家精准肿瘤学公司,主要针对与病毒相关的恶性肿瘤。Viracta的专有研究药物Nanatinostat,目前正在与抗病毒药valganciclovir组合作为口服联合疗法在EBV阳性淋巴瘤的2期临床试验中进行评估。Viracta正在将这种可诱导的合成致死性方法应用于其他与EBV相关的恶性肿瘤,例如鼻咽癌,胃癌和其他与病毒相关的癌症。
发行价格:
--
{"stockData":{"symbol":"VIRX","market":"US","secType":"STK","nameCN":"Viracta Therapeutics, Inc.","latestPrice":0.4985,"timestamp":1721764800000,"preClose":0.52,"halted":0,"volume":41493,"hourTrading":{"tag":"盘后","latestPrice":0.4881,"preClose":0.4985,"latestTime":"16:07 EDT","volume":238,"amount":116.09179707999999,"timestamp":1721765248649},"delay":0,"floatShares":24672506,"shares":39272434,"eps":-1.235558,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.0215,"latestTime":"07-23 18:22:17 EDT","open":0.51,"high":0.51,"low":0.4834,"amount":20617.139349,"amplitude":0.051154,"askPrice":0.5493,"askSize":100,"bidPrice":0.4418,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.235558,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721779200000},"adr":0,"listingDate":1127793600000,"adjPreClose":0.52,"postHourTrading":{"tag":"盘后","latestPrice":0.4881,"preClose":0.4985,"latestTime":"16:07 EDT","volume":238,"amount":116.09179707999999,"timestamp":1721765248649},"volumeRatio":0.371474,"impliedVol":0.376,"impliedVolPercentile":0.0833},"requestUrl":"/m/hq/s/VIRX","defaultTab":"news","newsList":[{"id":"2453565420","title":"Viracta Therapeutics, Inc.盘中异动 早盘股价大跌5.58%报0.491美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453565420","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453565420?lang=zh_cn&edition=full","pubTime":"2024-07-23 22:54","pubTimestamp":1721746487,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日22时54分,Viracta Therapeutics, Inc.股票出现波动,股价大幅下跌5.58%。Viracta Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。其相关个股中,Azitra Inc、Salarius Pharmaceuticals, Inc.、Adial Pharmaceuticals, Inc涨幅较大,Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc较为活跃,换手率分别为4592.02%、4400.47%、3158.91%,振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc,振幅分别为366.13%、365.43%、137.74%。Viracta Therapeutics, Inc.公司简介:Viracta Therapeutics Inc 是一家专注于开发针对与病毒相关恶性肿瘤的新药物的精准肿瘤学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723225447af93acdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723225447af93acdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VIRX","LENZ"],"gpt_icon":0},{"id":"2453796361","title":"Viracta Therapeutics, Inc.盘中异动 早盘大幅下挫8.68%报0.500美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453796361","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453796361?lang=zh_cn&edition=full","pubTime":"2024-07-22 22:04","pubTimestamp":1721657076,"startTime":"0","endTime":"0","summary":"北京时间2024年07月22日22时04分,Viracta Therapeutics, Inc.股票出现异动,股价急速下跌8.68%。Viracta Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.58%。其相关个股中,木薯科学、Mei Pharma, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大,Hepion Pharmaceuticals, Inc.、Scisparc Ltd.、Mei Pharma, Inc.较为活跃,换手率分别为109.20%、88.43%、26.31%,振幅较大的相关个股有Anew Medical Inc C/Wts 21/06/2029 、木薯科学、Hepion Pharmaceuticals, Inc.,振幅分别为44.07%、29.56%、27.45%。Viracta Therapeutics, Inc.公司简介:Viracta Therapeutics Inc 是一家专注于开发针对与病毒相关恶性肿瘤的新药物的精准肿瘤学公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722220436af937311&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722220436af937311&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VIRX","LENZ"],"gpt_icon":0},{"id":"2432758259","title":"Viracta Therapeutics Inc 预计每股亏损 35 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432758259","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432758259?lang=zh_cn&edition=full","pubTime":"2024-05-03 19:49","pubTimestamp":1714736942,"startTime":"0","endTime":"0","summary":" * Viracta Therapeutics Inc 预计在5月6日公布截至2024年3月31日的财报时,季度营收将不会有任何变化(预计) * * LSEG分析师对Viracta Therapeutics Inc的平均预期是每股亏损35美分。* 华尔街对 Viracta Therapeutics Inc 的 12 个月目标价中位数为 5.50 美元,高于其最新收盘价 0.84 美元。5月3日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VIRX"],"gpt_icon":0},{"id":"2417055302","title":"Viracta Therapeutics Inc 预计每股亏损 29 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2417055302","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417055302?lang=zh_cn&edition=full","pubTime":"2024-03-08 20:56","pubTimestamp":1709902600,"startTime":"0","endTime":"0","summary":" * Viracta Therapeutics Inc 预计在5月6日公布截至2024年3月31日的财报时,季度营收将不会有任何变化(预计) * * LSEG分析师对Viracta Therapeutics Inc的平均预期是每股亏损29美分。* 华尔街对 Viracta Therapeutics Inc 的 12 个月目标价中位数为 5.50 美元,高于上一交易日 0.81 美元的收盘价。3月8日 - 本摘要于北京时间 3 月 8 日 12:56 机器生成。(如对本报告中的数据有任何疑问,请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viracta.com","stockEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.1683},{"period":"3month","weight":-0.3866},{"period":"6month","weight":0.0019},{"period":"1year","weight":-0.6623},{"period":"ytd","weight":-0.0877}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.1427},{"period":"1year","weight":0.2266},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viracta Therapeutics, Inc.于1998年2月10日在特拉华州注册成立。其子公司主要位于南旧金山、加利福尼亚州。Viracta是一家精准肿瘤学公司,主要针对与病毒相关的恶性肿瘤。Viracta的专有研究药物Nanatinostat,目前正在与抗病毒药valganciclovir组合作为口服联合疗法在EBV阳性淋巴瘤的2期临床试验中进行评估。Viracta正在将这种可诱导的合成致死性方法应用于其他与EBV相关的恶性肿瘤,例如鼻咽癌,胃癌和其他与病毒相关的癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.473684,"avgChangeRate":0.07126},{"month":2,"riseRate":0.631579,"avgChangeRate":0.143175},{"month":3,"riseRate":0.526316,"avgChangeRate":0.062681},{"month":4,"riseRate":0.526316,"avgChangeRate":-0.003931},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.004094},{"month":6,"riseRate":0.315789,"avgChangeRate":-0.032856},{"month":7,"riseRate":0.473684,"avgChangeRate":-0.022357},{"month":8,"riseRate":0.388889,"avgChangeRate":0.000699},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.110622},{"month":10,"riseRate":0.315789,"avgChangeRate":-0.123636},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.026744},{"month":12,"riseRate":0.315789,"avgChangeRate":0.041195}],"exchange":"NASDAQ","name":"Viracta Therapeutics, Inc.","nameEN":"Viracta Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viracta Therapeutics, Inc.(VIRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viracta Therapeutics, Inc.(VIRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viracta Therapeutics, Inc.,VIRX,Viracta Therapeutics, Inc.股票,Viracta Therapeutics, Inc.股票老虎,Viracta Therapeutics, Inc.股票老虎国际,Viracta Therapeutics, Inc.行情,Viracta Therapeutics, Inc.股票行情,Viracta Therapeutics, Inc.股价,Viracta Therapeutics, Inc.股市,Viracta Therapeutics, Inc.股票价格,Viracta Therapeutics, Inc.股票交易,Viracta Therapeutics, Inc.股票购买,Viracta Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viracta Therapeutics, Inc.(VIRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viracta Therapeutics, Inc.(VIRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}